Advertisement

Topics

Obinutuzumab - Biotech, Pharma and Life Science Channel

01:11 EST 24th January 2019 | BioPortfolio

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.

Source: http://www.cancer.gov/drugdictionary?cdrid=570643

PubMed Articles [7 Associated PubMed Articles listed on BioPortfolio]

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.

The National Institute for Health and Care Excellence (NICE), as part of the institute's single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited)...

Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature.

Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and rel...

Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy.

Rituximab, a chimeric anti-CD20 monoclonal antibody (mAb), has been used in polyneuropathy associated with anti-MAG antibody polyneuropathy with controversial results. Herein, we report on two patient...

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Anti-CD20 monoclonal antibodies: reviewing a revolution.

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatmant of B cell hematological malignancies and have become a cornerstone of modern gold-stand...

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study.

Shorter duration of infusion of monoclonal antibody treatments may reduce treatment burden and improve healthcare resource utilization.

News Articles [20 Associated News Articles listed on BioPortfolio]

Obinutuzumab Beneficial For Reducing Early Progression in FL?

A study investigates whether FL patients had fewer early disease progression events when assigned to treatment with obinutuzumab plus chemotherapy.

Fixed-Duration Venetoclax Triplet Active in CLL

Kerry A. Rogers, MD, discusses phase II findings of a trial with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in chronic lymphocytic leukemia.

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia

Dr Carolina Moreno Atanasio speaks to ecancer at ASH 2018 about updates of the iLLUMINATE trial, which uses ibrutinib in combination with obinutuzumab to treat patients with chronic lymphocytic leukae...

Irutinib with obinutuzumab in patients with chronic lymphocytic leukaemia

Dr Carolina Moreno Atanasio speaks to ecancer at ASH 2018 about updates of the iLLUMINATE trial, which uses irutinib in combination with obinutuzumab to treat patients with chronic lymphocytic leukaem...

Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 22/07/2014, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 22/07/2014, Revision: 7, Status: Authorised

Janssen applies for expanded approval for IMBRUVICA in Europe

One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from The...

Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe

Applications submitted to the European Medicines Agency (EMA) for new combinations in adult patients with chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinemia ...

AbbVie’s Venetoclax Demonstrates Positive Results in Phase 3 Study as First-Line Therapy in Patients with Chronic Lymphocytic Leukemia

NORTH CHICAGO, Ill., Oct. 31, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive results from CLL14, a Phase 3, randomized cli...

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities

Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people wi...

Companies [1 Associated Companies listed on BioPortfolio]

Abreos Biosciences

Abreos Biosciences is focused on ligand binding assays for biologic and biosimilar drug development, activity validation, authentication, and precision dosing, as well as massivel...

Clinical Trials [77 Associated Clinical Trials listed on BioPortfolio]

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

CLL2-BAAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of debulking with bendamustine followed by induction and main...

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Background: Chronic lymphocytic leukemia (CLL) is a blood cancer. Recombinant human interleukin 15 (IL-15) is a manmade protein. Obinutuzumab is a protein made to deactivate cancer cells....

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Background: Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in the occidental countries. Until now, it is considered a chronic disease without a cure. The development of new...

Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax works in treating older patients with untreated chronic lymphocytic leukemia. Ibrutinib may stop...

Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of ca...

A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1

This is a multi-center, single-arm, open label, non-randomized, phase II study designed to investigate the efficacy, safety and tolerability of obinutuzumab given as monotherapy in patient...

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab in combination with polatuzumab vedotin in participants with B-cell non-Hodgkin lymphoma ...

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs...

An Open-Label Phase lB Study of RO7082859 and Atezolizumab in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combinatio...

Gazyva Infusion Reaction Investigation

The study evaluate safety and effectiveness of chlorambucil and obinutuzumab in routine clinical practice in patients with chronic lymphatic leukemia and with certain comorbidities (any ca...

Medical and Biotech [MESH] Definitions

None available.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...